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ABSTRACT 
Amoxicillin-clavulanate (AC) is one of the most common causes of drug induced liver injury 
(DILI). The association between AC-DILI and HLA alleles and the detection of drug-specific 
T cells in patients with AC-DILI indicate that the adaptive immune system is involved in the 
disease pathogenesis. In this study, mass spectrometric methods were employed to 
characterize the antigen formed by AC in exposed patients and the antigenic determinants 
that stimulate T cells. Amoxicillin formed penicilloyl adducts with lysine residues on human 
serum albumin (HSA) in vitro, with K190 and K199 being the most reactive sites. 
Amoxicillin-modified K190 and K199 have also been detected in all patients, and more 
extensive modification was observed in patients exposed to higher doses of amoxicillin. In 
contrast, the binding of clavulanic acid to HSA was more complicated. Multiple adducts were 
identified at high concentrations in vitro, including those formed by direct binding of 
clavulanic acid to lysine residues, novel pyrazine adducts derived from binding to the 
degradation products of clavulanic acid, and a cross-linking adduct. Stable adducts derived 
from formylacetic acid were detected in all patients exposed to the drug. Importantly, 
analysis of hapten-protein adducts formed in cell culture medium revealed that the highly 
drug-specific T-cell responses were likely driven by the markedly different haptenic 
structures formed by these two drugs. In this study the unique haptenic structures on albumin 
in patients formed by amoxicillin and clavulanic acid have been characterized and shown to 
function as chemically distinct antigens which can stimulate separate, specific T-cell clones. 
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INTRODUCTION 
Amoxicillin-clavulanate (AC) is a broad-spectrum antibiotic composed of amoxicillin and the 
β-lactamase inhibitor, clavulanic acid. AC is one of the most common associations with drug 
induced liver injury (DILI) in Europe and the US, 1, 2 and the incidence is considerably higher 
for AC combination prescriptions than for amoxicillin alone, 3, 4 indicating liver injury is 
directed by the clavulanic acid component. AC is typically associated with cholestatic injury, 
although mixed and hepatocellular patterns can occur, particularly in younger patients. Risk 
factors for hepatotoxicity include age (greater than 65 years), gender (female) and repeated 
course of the antibiotic. 4, 5 
The mechanism of amoxicillin-clavulanate–induced liver injury (AC-DILI) has not been fully 
defined. However, liver histology has shown infiltrates of lymphocytes, neutrophils and 
eosinophils in portal tracts in patients with cholestatic hepatitis following AC treatment. 6 
Several groups have also shown that AC-DILI was associated with expression of multiple 
HLA class I and II alleles 7-9 and the phenotypic expression of DILI can be influenced by a 
specific HLA genotype. For example, HLA class I alleles A*3002 and B*1801 were 
associated with hepatocellular injury, while the class II allele combination DRB1*1501- 
DQB1*0602 was associated with cholestatic/mixed type of liver damage. 9, 10 In addition, 
recent studies by Kim et. al 11 have demonstrated that both amoxicillin- and clavulanic acid-
specific T lymphocytes were detectable in patients who developed DILI. Collectively, these 
findings suggested that immune-mediated mechanisms might be involved in the disease. 
Importantly, amoxicillin and clavulanic acid responsive CD4(+) and CD8(+) T-cell clones 
were generated from DILI patients with and without HLA risk alleles, and mechanistic 
analysis suggested that all clones were activated with drug-protein adducts via a pathway 
dependent on the antigen presenting cells  processing machinery. 11 
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Studies by Ariza et. al have demonstrated that amoxicillin can form covalent adducts with 
serum proteins in vitro, such as human serum albumin (HSA), transferrin and 
immunoglobulin heavy and light chains, 12, 13.  Lys190, Ly199 and Lys541 appeared to be the 
most reactive sites on HSA. However, amoxicillin-modified proteins have not been detected 
in patients exposed to the drug. Clavulanic acid has been shown to form covalent adducts 
with Mycobacterium tuberculosis β-lactamase, leading to unique and irreversible inhibition. 
A stable adduct formed by clavulanic acid with a serine residue on the enzyme has been 
detected, along with several further degradation adducts. 14 However, formation of antigenic 
adducts that can drive drug specific immune responses and adducts that are actually formed 
in exposed patients have not been investigated. 
Thus, the antigenic determinants of AC formed in patients that could trigger immune 
responses and subsequently lead to liver injury remain to be determined. The purpose of this 
study was to (a) explore the molecular basis of amoxicillin and clavulanic acid binding to 
HSA in vitro; (b) define the precise haptenic structures formed by amoxicillin and clavulanic 
acid in cell culture; (c) determine whether similar adducts could be detected in patients; and 
(d) provide an immunochemical rationale for independent drug-specific T-cell responses to 
the two drugs in patients.  
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EXPERIMENTAL PROCEDUREs 
Chemicals. HSA (97-99% pure) and bovine serum albumin were purchased from Sigma-
Aldrich (St. Louis, MO), trypsin from Promega (Madison, WI), liquid chromatography-mass 
spectrometry (LC-MS) grade solvents from Fisher Scientific UK Ltd (Loughborough, 
Leicestershire), and all other standard reagents from Sigma-Aldrich.  
Patients.  Plasma samples were isolated from four patients without adverse drug reactions 
(ADRs) to AC, and stored immediately at -80°C. Table S1 summarizes the patients’ 
demographics and the clinical features of the ADRs. Approval for the study was acquired 
from the Liverpool and Leeds local research ethics committees; informed written consent was 
obtained from each patient.  
Concentration-Dependent Modification of HSA by AC In Vitro. Amoxicillin or clavulanic 
acid potassium salt freshly dissolved in potassium phosphate buffer (0.06-12 mM, pH 7.4) 
was incubated with HSA (0.6 mM, 50 µL) in sealed Eppendorf tubes at 37°C for 16 h. The 
molar ratios of drug to protein were 0.1:1, 1:1, 10:1, and 20:1. Protein was precipitated twice 
with 9 volumes of ice-cold methanol to remove free drug, resuspended in 50 µL phosphate 
buffer and then reduced with 10 mM dithiothreitol (15 min) and alkylated with 55 mM 
iodoacetamide (15 min) at room temperature. The protein was precipitated with methanol 
once more and finally dissolved in 100 µL 50 mM ammonium hydrogencarbonate, and 165 
µg (1.25 nmol) of protein was digested with 1.6 µg trypsin overnight at 37°C. The samples 
were processed for LC-MS/MS analysis as described previously.15  
Time-Dependent Modification of HSA by AC In Vitro. Amoxicillin or clavulanic acid 
potassium salt freshly dissolved in potassium phosphate buffer (10 mM, pH 7.4) was 
incubated with HSA (0.6 mM, 300 µL) at 37°C (final drug concentration, 6 mM). Aliquots of 
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50 µL were removed after 0.5, 1, 2, 3, 16 and 24 h and processed for LC-MS/MS analysis as 
described above. 
Mass Spectrometric Characterization of Clavulanic Acid NAL Conjugates. Freshly 
prepared clavulanic acid solution (10 mM in phosphate buffer, pH 7.4) was incubated with N-
acetyl lysine (10 mM) in the presence or absence of  NaCNBH3 (1 mM) at 37°C for 16 h. The 
resulting products were analyzed by LC-MS. Samples were delivered into a 4000 QTRAP 
(AB Sciex, Framingham, MA,) coupled with a 1260 Infinity Quaternary Pump HPLC system 
(Agilent Technologies, Santa Clara, CA) and Kinetex C18 column (2.6 µm C18, 100 mm × 
2.1 mm, Phenomenex, Macclesfield, Cheshire, U.K.). A gradient from 1% acetonitrile /0.1% 
formic acid (v/v) to 50% acetonitrile/0.1% formic acid (v/v) in 12 min was applied at a flow 
rate of 150 µL/min. Data were analyzed using Analyst software, version 1.5.1 (AB Sciex). 
Isolation of HSA from Plasma by Affinity Chromatography. HSA was isolated from 
patients’ plasma by affinity chromatography as described previously 16 with slight 
modifications. An Affinity Removal Column HSA Only (Agilent Technologies) attached to a 
Vision Workstation (Applied Biosystems) was used to affinity-capture HSA from 50 µL of 
freshly thawed plasma. The HSA was eluted with 12 mM HCl and precipitated with 9 
volumes of ice-cold methanol. The eluted protein was processed for LC-MS/MS analysis as 
described above. 
Mass Spectrometric Characterization of AC-Modified HSA. In order to characterize all 
potential amoxicillin or clavulanic acid-modified peptides, samples were analyzed using a Q-
TOF (AB Sciex) instrument by previous established methods. 17  Modified peptides were 
identified by filtering for specific fragment ions in PeakView 1.2.0.3 (AB Sciex) and manual 
inspection of the spectra. 
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For the semi-quantitative analysis of amoxicillin or clavulanic acid-modified peptides, 
samples were delivered into a QTRAP 5500 (AB Sciex) fitted with a NanoSpray II source by 
automated in-line liquid chromatography (U3000 HPLC System, 5 mm C18 nano-precolumn 
and 75 µm × 15 cm C18 PepMap column; Dionex, Sunnyvale, CA) via a 10 µm inner 
diameter PicoTip (New Objective, Woburn, MA). Multiple reaction monitoring (MRM) 
transitions specific for amoxicillin-modified peptides were selected as follows: the m/z values 
of precursor ions were calculated for all possible peptides containing a lysine residue with a 
mass addition of 365 amu together with the characteristic fragment ion of m/z 160 derived 
from amoxicillin as the product ion. MRM transitions for clavulanic acid-modified peptides 
were selected as follows: the m/z values of precursor ions were calculated for all possible 
peptides containing a lysine residue or histidine with a mass addition of 199, 155, 137, 70, 
and 222 amu together with appropriate “b” or “y” sequence ions as the product ions. MRM 
transitions were acquired at unit resolution in both the Q1 and Q3 quadrupoles to maximize 
specificity. They were optimized for collision energy and collision cell exit potential, and the 
dwell time was 20 ms. Total ion counts were determined from a second aliquot of each 
sample analyzed by conventional LC-MS and were used to normalize sample loading on the 
column. Relative quantification of modified peptides was performed by comparing the 
relative normalized intensity of MRM peaks for each of the modified residues against total 
ion counts across samples. Data were analyzed using Analyst software (AB Sciex). 
Western blotting. Aliquots of 5 µg proteins were separated by electrophoresis on a 10% 
SDS-polyacrylamide gel, and electroblotted onto nitrocellulose membrane. Non-specific 
binding was blocked using Tris/saline/Tween buffer (TST: NaCl, 150 mM; Tris-HCl, 10 mM; 
Tween 20, 0.05 %; pH 8.0) containing 10% non-fat dry milk for 16 h at 4°C. The blot was 
incubated with primary anti-penicillin antibody (mouse anti-penicillin monoclonal antibody; 
AbD Serotec) diluted 1:20,000 in 5% milk/TST for 1 h, followed by incubation with horse 
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radish peroxidise conjugated anti-mouse IgG antibody (Abcam) diluted 1:10,000 in 5 % 
milk/TST for a further 1 h. Signal was detected by enhanced chemiluminescence (Western 
Lightning, PerkinElmer, Boston, USA) using autoradiography film and a GS800 calibrated 
scanning densitometer (BioRad, Hemel Hempstead, UK). 
Generation of T-cell Clones from Patients with AC-induced Liver Injury. PBMCs were 
isolated from patients with AC-DILI. Approval for the study was acquired from the Liverpool 
local research ethics committee. PBMCs were cultured at 1x106 cells/well with amoxicillin, 
clavulanic acid and amoxicillin-clavulanate (0.1-1.0 mM) in RPMI 1640 supplemented with 
10% AB serum (Class A: Innovative Research Inc., Novi, MI), 25 mM HEPES, 10 mM of L-
glutamine and 20 µg/ml of transferrin (Sigma-Aldrich, Gliingham, UK). On days 6 & 9, 200 
IU/ml of recombinant interleukin (IL)-2 was added (PeproTech, London, UK). On day 13, T 
cells were cloned by serial dilution, as described previously. 18 Epstein-Barr virus (EBV)-
transformed B-cells were used as antigen presenting cells (APCs). APCs were transformed by 
adding supernatant from the EBV-producing cell line, B95.8. Clones were cultured for 48 h 
and cell proliferation was measured by the addition of [3H]thymidine for the final 16 hours of 
the assay (0.5 uCi/well, 5 Ci/mmol; Morovek Biochemicals, Brea, CA).  Clones with a 
stimulation index of 2 or above were determined to be drug specific. 
Concentration-dependent Response of AC-specific T-cell Clones. T-cell clones were 
tested for IFN-γ secretion after drug stimulation using ELIspot. T cells (5x104 cells/well) 
were cultured with autologous irradiated APC (1x104 cells/well) and amoxicillin or 
clavulanic acid for 48 h. Prior to developing the ELIspot, cell supernatants were removed for 
LC/MS/MS analysis.  
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RESULTS 
Characterization of Amoxicillin-HSA Adducts In Vitro. Amoxicillin, like other 
penicillins, was found to form penicilloyl adducts with lysine residues on proteins (Figure 
1A). The MS/MS spectrum of peptide 182LDELRDEGKASSAK195 (Figure 1B) confirmed the 
formation of amoxicillin-HSA adducts in vitro. The presence of characteristic fragment ions 
of m/z 160 and m/z 349, corresponding to the thiazolidine ring and the loss of amino group of 
amoxicillin, respectively, and a series of amoxicillin-adducted b and y ions provided 
substantial evidence of modification. This is consistent with previous findings. 12 Up to 12 
amoxicillin-modified Lys residues on HSA were detected after 24 h (at a drug/protein molar 
ratio of 20:1), with Lys190 and Lys 199 being the most reactive sites (Figure 1C). The level 
of modification increased progressively with drug concentration and incubation time 
(drug/protein molar ratio of 1:1) (Figure 1D). 
Characterization of Clavulanic Acid-N-Acetyl Lysine Adducts In Vitro. To probe the 
chemical basis of clavulanic acid’s covalent binding to nucleophiles, clavulanic acid was 
incubated with NAL with or without NaCNBH3 in phosphate buffer (10 mM, pH 7.4). The 
resulting mixture was analyzed by LC-MS/MS. A total of ten types of adduct were detected 
when clavulanic acid was incubated with NAL at high concentration (Scheme 1 and 2), 
including adducts formed by direct opening of beta-lactam ring, novel pyrazine adducts 
derived from binding to the degradation products of clavulanic acid, and a cross-linking 
adduct.  
The initial attack of the beta-lactam ring of clavulanic acid by NAL would generate an adduct 
with a mass addition of 199 amu (adduct A), however it is quickly decarboxylated to generate 
the +155 adduct (adduct B: m/z 344, Figure S1a, Supporting Information). Further reduction 
of the +155 adduct by NaCNBH3 confirmed the presence of imine functional group (m/z 346, 
Figure S1b, Supporting Information). Adduct B can be subsequently hydrolyzed or 
Page 10 of 36
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11 
 
dehydrated to generate adduct C and D respectively (m/z 362 and m/z 326, Figure S1c and d, 
Supporting Information). Further degradation of adducts A-D provided either adduct E 
(∆m=70 amu, m/z 259, Figure S1e) or cross-linking adduct H that can be stabilized by 
NaCNBH3 (∆m=54 amu, m/z 431, Figure S1f). Another two adducts with mass addition of 70 
amu were also detected (adduct G/F, m/z 259, Figure S1g), which can be reduced by 
NaCNBH3 (m/z 261, Figure S1h), indicating the presence of an imine functional group. 
Further mass spectrometric fragmentation suggested that these adducts were formed by the 
reaction of NAL with formylacetic acid, a degradation product derived from clavulanic acid. 
Clavulanic acid is known to undergo spontaneous hydrolysis under neutral or basic 
conditions, and pyrazine end-products can be formed via the reactive amino ketone (Scheme 
2). A pyrazine product (m/z 223, Figure 2A) was detected when calvulanic acid was 
incubated with NAL under neutral conditions (10 mM phosphate buffer, pH 7.4). In addition, 
two types of NAL-pyrazine adducts were also detected: adduct I with mass addition of 222 
amu and adduct J with mass addition of 310 amu (m/z 411 and m/z 499, Figure 2B and C). 
Characterization of Clavulanic Acid-HSA Adducts In Vitro. To characterize the putative 
protein adducts formed by clavulanic acid, HSA was incubated with a range of molar ratios 
of clavulanic acid (1:1 to 50:1). LC-MS/MS analysis of the tryptic digests revealed seven 
types of adducts, including direct binding of clavulanic acid to lysine residues, subsequent 
degradation products, and pyrazine adducts on lysine and histidine residues (Table I).  
The initial addition of clavulanic acid to lysine in HSA resulted in an adduct with a mass 
addition of 199 amu. Figure 3A shows a representative MS/MS spectrum for a triply charged 
ion at m/z 573.28, corresponding to the tryptic peptide 182LDELRDEGKASSAK195 with an 
additional mass of 199 amu. The peptide sequence was confirmed by fragmentations that 
generated partial singly charged y and b series ions. The modification site was confirmed by 
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b12* (m/z 750.89) and y13*(m/z 794.39) with adduction of 199 amu. The presence of a 
fragment ion of m/z 182 that derived from dehydrated clavulanic acid provided further 
evidence of the modification. In addition to modification on Lys190, two more sites (Lys414 
and 525) were also modified with full mass addition (Table I). The +199 adducts had 
undergone further degradation to form the +154 and +137 adducts, which were detected at 
multiple sites on HSA (Figure S2a and b, Table I). The end adducts appeared to be quite 
stable and have a mass addition of 70 amu. A typical MS/MS spectrum representing the 
tryptic peptide 525KQTALVELVK534 with a mass addition of 70 amu is shown in Figure 3B. 
The mass increment of 70 amu could be attributed to adduct E or F/G, however, 
simultaneous observation of the reduced +72 adducts indicates that the +70 adducts are most 
likely derived from formylacetic acid (Figure S2c).  A total of eleven lysine residues and one 
histidine residue were found to be adducted with 70 amu when clavulanic acid was incubated 
with HSA at a molar ratio of 20:1 (Table I). 
Similar to the modifications observed with NAL, stable adducts derived from pyrazine were 
also detected on multiple sites including eleven lysine residues and two histidine residues 
(Table I). Figure 3C shows a representative MS/MS spectrum for a triply charged ion at m/z 
707.72, corresponding to the tryptic peptide 145RHPYFYAPELLFFAK160 with an additional 
mass of 222 amu. The observation of a fragment ion of m/z 223 and the subsequent fragment 
ions (m/z 205 and 193) indicates the presence of pyrazine modification. In addition, the 
modification site was confirmed by b4* (2+, m/z 388.7), b5* (2+, m/z 462.3), and b5* (m/z 
1086.6), all with a mass addition of 222 amu, giving evidence of modification at His146 
(Figure 3C).  
Concentration Dependence of HSA Modification with Clavulanic Acid. The modification 
of HSA by clavulanic acid was found to be concentration-dependent. A semi-quantitative 
analysis of modification at each site was performed by determining the area under the curve 
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for the extracted masses of the modified peptides, followed by normalization of the ion 
intensity against the total ion count for the sample. Notwithstanding the disparity in the 
ionization efficiency of the peptides, the epitope profile (the relative abundance of clavulanic 
acid-modified peptides) revealed that the pyrazine adducts were preferentially formed on 
Lys159, 212 and 525; whereas Lys190 was more likely targeted by formylacetic acid (Figure 
4A and B). The total level of the pyrazine adducts increased with increased molar ratio of 
drug to protein, whereas the total level of the +70 adducts declined when the concentrations 
of clavulanic acid increased, indicating pyrazine adducts were formed predominately with 
high concentration of clavulanic acid (Figure 4C and D). A concentration-dependent increase 
in normalized ion counts was also observed for each modified peptide (Figure 4E and F), 
except for the +70 Lys190 adduct.  
Effects of Clavulanic Acid on Covalent Binding of Amoxicillin to HSA. In order to 
determine the effect of clavulanic acid on amoxicillin covalent binding, clavulanic acid was 
co-incubated with amoxicillin and HSA at different concentrations (0.625-2.5 mM). There 
was only a slight difference with respect to the epitope profiles of amoxicillin binding to 
HSA in the presence of clavulanic acid (Figure S3A). The optimal binding of amoxicillin to 
HSA was found when incubated with amoxicillin and clavulanic acid at the molar ratio of 
2:1, indicating there was a balance in the role of clavulanic acid between preventing 
amoxicillin hydrolysis and competitive binding to proteins.  These findings were also 
confirmed by Western blot data (Figure S3B). 
Modification of HSA by Amoxicillin-Clavulanic Acid in Patients. We next investigated 
whether the same adducts could be formed in patients receiving AC therapy. HSA was 
isolated from four patients receiving AC either orally or intravenously, and AC-modified 
albumin was detected in all patients (Table II). Amoxicillin modification of HSA was 
detected at up to 8 lysine residues in patients receiving higher doses of AC, and amoxicillin-
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modified K190 was detected in all patients. Interestingly, MS/MS analysis also revealed a 
novel adduct that was formed by amoxicillin dimer (Figure 5A). The observed triply charged 
ion of m/z 750.34 corresponds to peptide 182LDELRDEGKASSAK195 with a mass increment 
of 730 amu, which could be assigned as two molecules of amoxicillin. The presence of 
characteristic fragment ions derived from amoxicillin (m/z 160, m/z 217, and m/z 349, Figure 
1A) confirmed the modification. The modification was further substantiated by the observed 
triply charged ion of m/z 744.68, corresponding to 2 amoxicillin adducted peptide with 
elimination of amino group, and doubly charged ion of m/z 1045.49 that could be assigned as 
2 amoxicillin adducted peptide after losing the thiazolidine group. 
The profile of clavulanic acid-modified peptides in patients is less complicated than in vitro. 
Only the +70 adducts were detected, with Lys190 adducts being detected in all patients 
(Table II).  Figure 5B shows a typical MS/MS spectrum for a triply charged ion of m/z 
530.27, corresponding to peptide 182LDELRDEGKASSAK195 with modification at Lys 190. 
Interestingly, several piperacillin-modified peptides have also been detected in these patients 
who had stopped the medication long before the bloods were taken (Table II and Figure S4), 
indicating drug protein adducts can remain in the body for a long time period. 
Drug-Antigen Specificity of T-Cell Clones. Proliferation of amoxicillin and clavulanic acid-
responsive CD4+ and CD8+ clones and the release of IFN-γ was drug concentration-
dependent. Responses were detected between 0.5 and 2 mM for amoxicillin, while the level 
of clavulanic acid required to trigger responses was much lower than that of amoxicillin, 
ranging from 50-200 μM (Figure 6A and B). Clones were tested for reactivity against 
amoxicillin and clavulanic acid, and the response to each drug was found to be highly 
specific (results not shown). Mass spectrometric analysis of covalent binding of drugs to 
albumin in cell culture medium demonstrated that amoxicillin bound the same group of lysine 
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residues that were identified in vitro and in patients (Figure 6C). In addition, the +70 adduct 
and pyrazine adducts derived from clavulanic acid were also detected when cells were 
exposed to clavulanic acid (Figure 6D).   
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DISCUSSION 
Accumulative data suggests that immune-mediated mechanisms are involved in AC-DILI. In 
particular, recent findings indicated that AC responsive T-cell clones are activated by a 
hapten mechanism involving the formation of hapten protein adducts followed by antigen 
processing.11  To probe the molecular and immunochemical mechanisms involved in AC-
DILI we have investigated the haptenation of HSA by amoxicillin and clavulanic acid in vitro 
and in patients.  Using advanced mass spectrometric techniques, we have demonstrated that 
amoxicillin and clavulanic acid form distinct multiple haptenic structures with HSA in vitro. 
More importantly, similar adducts were detected in patients receiving AC therapy, and AC 
responsive T-cell clones were activated by the same adducts formed in cell culture.  
The chemistry of amoxicillin binding to proteins is relatively straightforward and similar to 
other penicillins that have been investigated by mass spectrometry both in vitro and in vivo. 
17, 19-21
 Amoxicillin is prone to nucleophilic attack at the β-lactam ring to form covalent 
adducts with several, but not all, of the lysine residues in albumin. Amoxicillin lysine adducts 
were detected in various serum proteins in vitro, 12 however, neither the amoxicillin adducts 
formed in exposed patients nor the functions of these protein adducts has been investigated. 
In this study, up to eleven amoxicillin-modified lysine residues in albumin were detected in 
exposed patients. Furthermore, adducts formed by an amoxicillin-dimer were seen in the 
same patients. This observation is important since amoxicillin polymers could possess strong 
antigenic properties. 22, 23 Following antigen processing, a range of amoxicillin-modified 
HLA class I (8-12mers) and class II binding peptides (9-25mers) will  be generated that may 
interact preferentially, but not exclusively, with proteins encoded by the HLA risk alleles 
identified in genetic studies (e.g., HLA-A*02:01, DRB1*15:01 and DQB1*06:02). 9 
 
Page 16 of 36
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17 
 
In contrast, the formation of potential antigenic adducts with clavulanic acid is much more 
complex. Clavulanic acid also contains a beta-lactam ring; however, it has important 
chemical differences to amoxicillin: first, it lacks a side chain; and second, the thiazolidine 
ring has been substituted by an oxazolidine. The structural differences may result in the 
formation of antigenic determinants, which are, in an immunochemical sense, quite distinct 
from those formed from β-lactam antibiotics. Clavulanic acid undergoes hydrolysis under 
neutral or basic condition, at a rate that is approximately 10 times faster than the hydrolysis 
of penicillin G. 24 The initial hydrolysis product is unstable: further decomposition products 
might be formed by the fission of the C-O bond on the oxapenam ring, decarboxylation, 
and/or hydrolytic elimination of formylacetic acid. 25 The degradation of clavulanic acid is 
self-accelerated at higher concentration because clavulanic acid and its decomposition 
products act as similarly strong general-base catalysts. 26 This is consistent with our 
observation that the pyrazine-type products were preferentially formed at high concentrations 
of clavulanate. Similar to the hydrolysis, the initial attack of a lysine residue on the beta-
lactam ring of clavulanate results in an unstable adduct, which would generate multiple 
haptenic adducts following further decomposition. These adducts are unique and have 
markedly different structures to amoxicillin haptenic adducts. Analysis of the proliferative 
response and cytokine release from T-cell clones revealed that there was no cross-reactivity 
between amoxicillin- and clavulanic acid. Our mass spectrometric data showing divergent 
haptenic structures on protein provides a chemical explanation for the drug-specific T-cell 
responses. 
Notably, a total of seven types of clavulanate-HSA adducts were identified in in vitro 
incubations. Interestingly, both the +70 adducts and pyrazine adducts were also identified in 
cell culture medium. Furthermore, the +70 adducts were also detected in exposed patients, 
reaffirming the relevance of in vitro studies. However, it is important to bear in mind that 
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although in vitro incubation is necessary for identification of all possible adducts, the in vitro 
data do not always mirror what occurs in patients. Considering the relatively long half-life of 
HSA in vivo (21 days), 27 the multiple doses of AC taken by patients, and the stability of the 
adducts, it is plausible that only adducts with great plasma stability would have accumulated 
in the plasma, leading to different binding profiles than that occurring in vitro. Likewise, the 
clavulanate-HSA adducts may be different from the acute binding of clavulanate to hepatic 
proteins, which may be responsible for AC-DILI. It is therefore important to develop 
sensitive methods for characterization of clavulanate adducts formed in liver and investigate 
the role of these adducts in AC-DILI. 
The hydrolysis of beta-lactam antibiotics by bacterial beta-lactamase is the major cause of 
bacterial resistance to this group of compounds, and the combination of amoxicillin and 
clavulanic acid has an increased spectrum of action and restored efficacy against amoxicillin-
resistant bacteria that produce β-lactamase. However, the addition of clavulanic acid to 
amoxicillin increases the risk of DILI. 28 The most probable explanation for the increased 
DILI risk is that the addition of clavulanic acid generates novel antigenic determinants that 
are distinct from those generated by amoxicillin alone, thus increasing the chemical repertoire 
of antigenic structures in patients which in turn may increase the possibility of immune 
recognition in an HLA restricted manner. Additional mechanisms suggested by the present 
study include selective targeting of the liver by clavulanic acid (or amoxicillin), and increased 
hepatic stress signaling by reactive degradation products of clavulanic acid, such as 
formylacetic acid, which could promote co-stimulatory signaling and the recruitment of 
inflammatory cells.  Future studies will require novel model systems to investigate the 
relationship between amoxicillin and/or clavulanic acid antigen formation in the liver and the 
activation of cytolytic T cells that target the liver.  However, it is important to note that the 
greater the varieties of antigens that are generated by a drug (combination) there will be a 
Page 18 of 36
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19 
 
paradoxical decrease in the potential for highly selective HLA restriction and thus the 
possibility of genotyping patients to predict those at enhanced risk of an adverse drug 
reaction. 
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AC, Amoxicillin-clavulanate; DILI, drug-induced liver injury; NAL, N-α-acetyl-lysine; LC-
MS/MS, liquid chromatography-tandem mass spectrometry; HSA, human serum albumin; 
ADR, adverse drug reactions; MRM, multiple reaction monitoring. 
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Table 1. Amoxicillin and Clavulanic acid-modified albumin peptides detected in vitroa  
Lysine Peptides Amox 
adducts 
Clavulanic acid adducts 
A 
∆m=199/
181 
B 
∆m=155 
D 
∆m=137 
E/F 
∆m=70 
I 
∆m=222 
K12 FK*DLGEENFK √   √ √ √ 
K137 K*YLYEIAR √  √ √ √ √ 
K159 RHPYFYAPELLFFAK*R     √ √ 
K162 YK*AAFTECCQAADK √      
K190 LDELRDEGK*ASSAK √ √ √ √ √ √ 
K195 ASSAK*QR      √ 
K199 LK*CASLQK √   √ √ √ 
K212 AFK*AWAVAR √   √ √ √ 
K351 LAK*TYETTLEK √   √ √ √ 
K414 K*VPQVSTPTLVEVSR  √  √ √ √ 
K432 NLGK*VGSK √    √ √ 
K436 VGSK*CCK √      
K475 VTK*CCTESLVNR √      
K525 K*QTALVELVK √ √  √ √ √ 
K541 ATK*EQLK √    √ √ 
H146 RH*PYFYAPELLFFAK     √ √ 
H338 RH*PDYSVVLLLR      √ 
 
aHSA was incubated with amoxicillin or clavulanic acid at drug protein molar ratio of 20:1 for 24 h, tryptic 
peptides of HSA were characterized by LC-MS/MS 
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Table 2. Amoxicillin and Clavulanic acid-modified albumin peptides detected in patientsa 
Patient Modification detected 
Amoxicillin piperacillin Clavulanic acid 
P3 (ML) K190 K190, K541 K190 
P1 (ST) K190 K190 K190 
P2 (TS) K541, K432, K190, K351, 
K525, K199 
K541, K190 K190, K199, K525 
P4 (79/F) K541, K432, K190, K351, 
K525, K199, K137 
K541, K190, K195, 
K432 
K190, K199, K525 
 
aThe drug-modified tryptic peptides of HSA isolated from the patients’ plasma were 
characterized by LC-MS/MS 
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FIGURE LEGENDS 
Figure 1. Characterization of amoxicillin-HSA adducts formed in vitro. Chemical 
structure of  penicilloyl adduct formed by amoxicillin and HSA (A); representative MS/MS 
spectrum of the albumin peptide 182LDELRDEGKASSAK195 modified at Lys190 with 
amoxicillin, characteristic fragment ions derived from partial cleavage of the hapten are 
circled (B); epitope profile showing the lysine residues of albumin modified after 24 h 
incubation at drug/protein molar ratio of 10:1 (C); the level of modification is concentration- 
and time-dependent (drug/protein molar ratio 1:1) (D).  
Figure 2. LC-MS/MS analysis of clavulanic acid degradation products and N-acetyl 
lysine adducts identified in vitro incubation in phosphate buffer (pH 7.4). MS/MS spectra 
showing the formation of pyrazine degradation product (A); a N-acetyl lysine adduct with 
mass addition of 222 amu (B); a N-acetyl lysine adduct with a mass addition of 310 amu (C). 
Figure 3. LC-MS/MS analysis of clavulanic acid modified HSA peptides identified in 
vitro. MS/MS spectra showing peptide 182LDELRDEGKASSAK195 was modified by 
clavulanic acid at Lys190 with a mass addition of 199 amu, indicating a full molecule was 
attached to Lys190 (A); peptide 525KQTALVELVK534 was modified at Lys525 with a mass 
addition of 70 amu (B); peptide 145RHPYFYAPELLFFAK159 was modified at His146 with a 
mass addition of 222 amu, indicating the formation of a pyrazine adduct (C). 
Figure 4. LC-MS/MS analysis of clavulanic acid-modified albumin peptides identified in 
vitro incubation with HSA. Clavulanic acid was incubated with HSA in phosphate buffer 
(10 mM, pH7,4) at molar ratio of 10:1. Epitope profile showing the amino acid residues of 
albumin modified in vitro with a mass addition of 222 amu (A) and 70 amu (B); the total 
level of modification is concentration dependent (C and D for the +222 and the +70 adducts, 
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respectively); concentration-dependent modification of individual amino acid residue was 
also observed ( E and F)  
Figure 5. LC-MS/MS analysis of modified HSA peptides identified in patients receiving 
amoxicillin-clavulanic acid therapy. MS/MS spectra showing peptide 
182LDELRDEGKASSAK195 was modified at Lys190 with a mass addition of 730 amu, 
indicating an amoxicillin dimer was attached to Lys190 (A); clavulanic acid-modified peptide 
182LDELRDEGKASSAK195 with a mass addition of 70 amu (B).  
Figure 6. Activation of T-cell clones with amoxicillin and clavulanic acid and analysis of 
drug-protein binding in culture medium. IFN-γ ELIspot of amoxicillin and clavulanic acid 
specific clones were generated from patient PBMCs. Drug specific clones were selected 
based upon a stimulation index of 2-fold or higher. Clones A6, A18, C23 and C30 
demonstrated IFN-γ cytokine release and proliferation in a dose dependent manner (A,B); the 
epitope profile shows the lysine residues of albumin modified by amoxicillin (C) and 
clavulanic acid (D) under cell culture conditions 
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SCHEME LEGENDS 
Scheme 1. Proposed pathways for the formation of clavulanic acid-protein adducts 
Scheme 2. Pathways for the degradation of clavulanic acid (A)24, 25 and the formation of 
pyrazine adducts in phosphate buffer (B). 
Scheme 1. Proposed pathways for the formation of clavulanic acid-protein adducts 
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Scheme 2. Pathways for the degradation of clavulanic acid (A)24, 25 and proposed pathways 
for the formation of pyrazine N-acetyl lysine adducts in phosphate buffer (B). 
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Figure 1. Characterization of amoxicillin-HSA adducts formed in vitro. Chemical structure of  
penicilloyl adducts formed by amoxicillin and HSA (A); representative MS/MS spectrum of the 
albumin peptide 182LDELRDEGKASSAK195 modified at Lys190 with amoxicillin, characteristic 
fragment ions derived from partial cleavage of the hapten are circled (*indicates drug 
modification) (B); epitope profile showing the lysine residues of albumin modified after 24 h 
incubation at drug/protein molar ratio of 10:1 (C); the level of modification is concentration-and 
time-dependent (drug/protein ratio of 1:1) (D).  
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Figure 2 
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Figure 2. LC-MS/MS analysis of clavulanic acid degradation products and N-acetyl lysine 
adducts identified in vitro incubation in phosphate buffer (pH 7.4). MS/MS spectra showing the 
formation of pyrazine degradation product (A); a N-acetyl lysine adduct with mass addition of 222 
amu (B); a N-acetyl lysine adduct with a mass addition of 310 amu (C). 
m/z 223 
m/z 411 
m/z 499 
Page 32 of 36
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 3 
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Figure 3. LC-MS/MS analysis of clavulanic acid modified HSA peptides identified in vitro. 
MS/MS spectra showing peptide 182LDELRDEGKASSAK195 was modified by clavulanic acid at 
Lys190 with a mass addition of 199 amu, indicating a full molecule was attached to Lys190 (A); 
peptide 525KQTALVELVK534 was modified at Lys525 with a mass addition of 70 amu (B); peptide 
145RHPYFYAPELLFFAK159 was modified at His146 with a mass addition of 222 amu, indicating the 
formation of a pyrazine adduct (C). (*indicates drug modification).  
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Figure 4. LC-MS/MS analysis of clavulanic acid-modified albumin peptides identified in vitro 
incubation with HSA. Clavulanic acid was incubated with HSA in phosphate buffer (10 mM, 
pH7,4) at molar ratio of 10:1. Epitope profile showing the amino acid residues of albumin 
modified in vitro with a mass addition of 222 amu (A) and 70 amu (B); the total level of 
modification is concentration dependent (C and D for the +222 and the +70 adducts, 
respectively); concentration-dependent modification of individual amino acid residue was also 
observed ( E and F)  
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Figure 5. LC-MS/MS analysis of modified HSA peptides identified in patients receiving amoxicillin-
clavulanic acid therapy. MS/MS spectra showing peptide 182LDELRDEGKASSAK195 was modified at 
Lys190 with a mass addition of 730 amu, indicating an amoxicillin dimer was attached to Lys190 (A); 
clavulanic acid-modified peptide 182LDELRDEGKASSAK195 with a mass addition of 70 amu (B).  
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Figure 6 
0.0E+00
5.0E+05
1.0E+06
1.5E+06
2.0E+06
2.5E+06
3.0E+06
K12 K137 K190 K199 K351 K432 K525 K541
N
o
rm
al
is
e
d
 io
n
 c
o
u
n
ts
 
0.0E+00
4.0E+05
8.0E+05
1.2E+06
1.6E+06
K12 K137 K190 K195 K199 K212 K351 K525
N
o
rm
al
is
e
d
 io
n
 c
o
u
n
ts
 
Δm=222 
Δm=70 
0 
0.5 
1 
1.5 
2 
A6 A18 C23 C30 
0 
0.05 
0.1 
0.15 
0.2 
mM mM 
Amoxicillin Specific Clones Clavulanic Specific Clones 
0
100
200
300
0 0.5 1 1.5 2
A6 
0
50
100
150
200
0 0.5 1 1.5 2
A18 
0
200
400
600
0 50 100 150 200
C23 
0
200
400
600
0 50 100 150 200
C30 
Sp
o
t 
C
o
u
n
t 
Amoxicillin (mM) 
Clavulanic Acid (µM) 
Figure 6. Activation of T cell clones with amoxicillin and clavulanic acid and analysis of drug-
protein binding in culture medium. IFN-γ ELIspot of amoxicillin and clavulanic acid specific 
clones were generated from patient PBMCs. Drug specific clones were selected based upon a 
stimulation index of 2-fold or higher. Clones A6, A18, C23 and C30 demonstrated IFN-γ 
cytokine release and proliferation in a dose dependent manner (A, B); the epitope profile 
shows the lysine residues of albumin modified by amoxicillin (C) and clavulanic acid (D) under 
cell culture conditions. 
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